NL
DE
9 July 2018
For the first time, patient-derived complex I-deficient primary skin fibroblasts are effectively protected against the toxicity of exogenous hydrogen peroxide by the action of internalized catalase-loaded nanoreactors, showcasing this system in a therapeutically relevant context.
The work was performed by PhD candidate Lisanne van Oppen and co-workers in the laboratories of Biochemistry and Pediatrics, theme Mitochondrial diseases, of the Radboudumc and assistant professor Loai Abdelmohsen and co-workers in the research group of Bio-Organic Chemistry at the Eindhoven University of Technology.
Researchers of the Radboudumc and colleagues, have successfully developed enzyme-loaded polymersomal nanoreactors capable of undergoing cellular integration in a controlled fashion and, subsequently, function as synthetic organelles. They published their findings in ACS Central Science.
For the first time, patient-derived complex I-deficient primary skin fibroblasts are effectively protected against the toxicity of exogenous hydrogen peroxide by the action of internalized catalase-loaded nanoreactors, showcasing this system in a therapeutically relevant context.
The work was performed by PhD candidate Lisanne van Oppen and co-workers in the laboratories of Biochemistry and Pediatrics, theme Mitochondrial diseases, of the Radboudumc and assistant professor Loai Abdelmohsen and co-workers in the research group of Bio-Organic Chemistry at the Eindhoven University of Technology.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Hans Spelbrink is beneficiary of the MITGEST Doctoral Network which receives 2.6 million euros funding (PhD positions available)
27 September 2022EU has granted the new Doctoral Network “MITGEST” (Quality Control of the Mitochondrial Gene Expression System in Health and Disease), of which Radboudumc is one of the partners, with 2.6 million euros of funding under the Marie Sklodowska-Curie Actions.
read more
Werner Koopman 25 years at Radboudumc celebrating online
8 July 2020 Werner Koopman completed his 25 years at Radboudumc. Biochemistry sent him a cake at home and celebrated this special moment during COVID-19 in a unique way. read more
Khondrion begins study on optimal dosage of new drug
10 February 2020 Pharmaceutical company Khondrion, a spin-off from Radboudumc, has taken another important step in the development of its drug sonlicromanol. The first patients have used the drug as part of a phase 2b study, which focuses on determining the optimum dose and efficacy. read more
New mitochondrial DNA maintenance disease uncovered
1 October 2019 The group of Hans Spelbrink, theme Mitochondrial diseases, and colleagues, has identified and characterized mutations in the mtDNA maintenance gene SSBP1 in families with optic atrophy and foveopathy. This paper is now online in The Journal of Clinical Investigation. read more
Grant to study mitochondrial morphofunction in Parkinson’s disease
14 March 2019 Werner Koopman, theme Mitochondrial diseases, received 400,000 euro as a member of the PD-MitoQUANT consortium. The latter is an EU-funded Innovative Medicines Initiative research project that will improve our understanding of Parkinson’s so that better treatments can be developed in the future. read more
